Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  DallaPiazza, Michelle ^a   Amorosa, Valerianna K ^b,c   Localio, Russell ^b   Kostman, Jay R ^b   Lo Re III, Vincent ^b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; VIREMIA; BLOOD; HEPATITIS C; LIVER CIRRHOSIS; MIDDLE AGED; THROMBOCYTE COUNT;

ADULT; ASPARTATE AMINOTRANSFERASES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREVALENCE; RISK FACTORS;

EID: 77952085462     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-116     Document Type: Article

References (33)

1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166(15):1632-1641. 10.1001/archinte.166.15.1632, 16908797.
2. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009, 4(2):e4517. 10.1371/journal.pone.0004517, 2637977, 19223976.
3. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006, 42(2):177-182. 10.1097/01.qai.0000221683.44940.62, 16688096.
4. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19(6):585-592. 10.1097/01.aids.0000163935.99401.25, 15802977.
5. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fischer HP, Oldenburg J, Brackmann HH, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996, 91(12):2563-2568.
6. Castellares C, Barreiro P, Martin-Carbonero L, Labarga P, Vispo ME, Casado R, Galindo L, Garcia-Gasco P, Garcia-Samaniego J, Soriano V. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008, 15(3):165-172.
7. Sulkowski MS, Mehta S, Montes de Occa R, Moore RD, Thomas DL. Estimated prevalence of significant liver disease among 4,052 HIV-infected adults with and without chronic hepatitis B and C. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA. February 5-8, 2006 [Abstract 842].
8. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005, 6(6):375-378. 10.1111/j.1468-1293.2005.00330.x, 16268817.
9. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005, 43(1):78-84. 10.1016/j.jhep.2005.02.025, 15894397.
10. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, Heeren T, Koziel M, Graham C, Craven DE, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005, 40(5):538-544. 10.1097/01.qai.0000184856.31695.bf, 16284529.
11. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, Rios-Villegas MJ, Ruiz-Morales J, Rivero A, del Valle J, Luque R, Rodriguez-Bano J, Gonzalez-Serrano M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007, 46(3):622-630. 10.1002/hep.21757, 17659577.
12. Loulergue P, Callard P, Bonnard P, Pialoux G. Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients. J Acquir Immune Defic Syndr 2007, 45(3):365.
13. Ryan P, Blanco F, Garcia-Gasco P, Garcia-Merchan J, Vispo E, Barreiro P, Labarga P, Gonzalez-Lahoz J, Soriano V. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009, 10(1):53-59. 10.1111/j.1468-1293.2008.00651.x, 19018879.
14. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003, 125(6):1695-1704. 10.1053/j.gastro.2003.08.032, 14724822.
15. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C, Garcia-Garcia JA, Lozano F, Gomez-Mateos JM, Pineda JA. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004, 18(5):767-774. 10.1097/00002030-200403260-00007, 15075511.
16. Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. AIDS 2008, 22(1):1-13. 10.1097/QAD.0b013e3282f0e2fd, 18090386.
17. Lo Re V, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007, 44(3):315-320. 10.1097/QAI.0b013e31802ea499, 17159655.
18. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526. 10.1053/jhep.2003.50346, 12883497.
19. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300(5):555-570. 10.1001/jama.300.5.555, 18677028.
20. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. 1993, New York: Chapman and Hall.
21. Lo Iacono O, Venezia G, Petta S, Mineo C, De Lisi S, Di Marco V, Rodolico V, Amato M, Ferraro D, Giordano C, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007, 25(10):1181-1191.
22. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34(4 Pt 1):738-744. 10.1053/jhep.2001.28055, 11584370.
23. Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol 2009, 43(8):758-764. 10.1097/MCG.0b013e31818be17c, 19238091.
24. Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008, 103(5):1136-1144. 10.1111/j.1572-0241.2008.01813.x, 18477344.
25. Taura N, Ichikawa T, Hamasaki K, Nakao K, Nishimura D, Goto T, Fukuta M, Kawashimo H, Fujimoto M, Kusumoto K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006, 101(12):2752-2759. 10.1111/j.1572-0241.2006.00835.x, 17026566.
26. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362. 10.1002/hep.510300604, 10573511.
27. Jaskiewicz K, Rzepko R, Sledzinski Z. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci 2008, 53(3):785-788. 10.1007/s10620-007-9942-x, 17846888.
28. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42(1):132-138. 10.1016/j.jhep.2004.09.012, 15629518.
29. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296. 10.1056/NEJMoa062360, 17135583.
30. Tuyama A, Hong F, Mosoian A, Chen P, Fiel I, Schecter A, Klotman M, Bansal M. HIV entry and replication in stellate cells promotes cellular activation and fibrogenesis: Implications for hepatic fibrosis in HIV/HCV co-infection. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. February 3-6, 2008 [Abstract 57].
31. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001, 26(4):340-344.
32. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000, 38(2):575-577. 86151, 10655348.
33. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Cano P, Mira JA, Arizcorreta-Yarza A, Ruiz-Morales J, Lomas-Cabeza JM, Garcia-Garcia JA, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006, 55(3):409-414. 10.1136/gut.2005.065904, 1856097, 16118349.